News coverage

Dr Andreas Kremer and Dr Marlyn Mayo highlight key advances in primary biliary cholangitis from AASLD The Liver Meeting 2025, and provide quick insights into the latest data on next-generation therapies.

Marlyn Mayo reviews RESPONSE analyses on seladelpar symptom effects in PBC.

Giving seladelpar beyond 12 months offers primary biliary cholangitis patients improvements in pruritus and biochemical markers, show ongoing analyses.

An analysis of trial data indicates that, alongside reducing pruritus, volixibat helps normalize fatigue and sleep in PBC patients.

A correlation between PRO-C3 and liver measures in PBC suggests it could represent a novel disease biomarker.

ELATIVE open-label extension trial findings support long-term elafibranor treatment in patients with PBC.

Mark Swain on 3-year elafibranor benefits, proteomics in PBC.

Discussing the ASSURE findings for seladelpar in PBC with Daniel Pratt.

Andreas Kremer explains post-hoc analysis findings from the phase 3 GLISTEN trial showing an effect of linerixibat on biomarkers and mediators of pruritus in patients with PBC.

Real-world evidence supports seladelpar use in patients with PBC initiating seladelpar second-line or switching from obeticholic acid.

Andreas Kremer discusses post-hoc analyses from the ELATIVE trial showing independent improvement in patient-reported outcomes with elafibranor for patients with PBC and efficacy irrespective of BMI.

Dr Marlyn Mayo and Dr Andreas Kremer discuss what’s ahead at AASLD 2025, with a focus on advances in primary biliary cholangitis and primary sclerosing cholangitis. They share their perspectives on emerging research, key topics to watch, and what they are most looking forward to at this year’s meeting.

Dr Richard Thompson and Dr Verena Keitel-Anselmino discuss the latest updates on IBAT inhibitors from EASL 2025, including their potential use in PBC patients based on promising phase I and II trial results.

Stay up to date with the latest in Primary Biliary Cholangitis with downloadable summaries of key trials from the 2024 AASLD Liver Meeting.

Dr Adriaan Van der Meer shares his insights on the results from the combination trial of obeticholic acid and bezafibrate for PBC patients, presented at EASL 2024 in Milan, Italy. In addition, discover key findings and learn about the RECAPITULATE trial, focusing on real-world treatment outcomes.

Professor Mark Swain discusses the latest updates from the ASSURE trial of seladelpar, presented at EASL 2024, in Milan, Italy. Explore key findings on efficacy, safety, and interim long-term results of this study.

Professor Marco Carbone reviews the latest updates from the ELATIVE trial of elafibranor, presented at EASL 2024 in Milan, Italy. Discover key insights on efficacy, quality of life improvements, and the broader significance of these results.

ASSURE study findings show that seladelapr elicits a biochemical response in patients with primary biliary cholangitis and cirrhosis.

ELATIVE subanalysis confirms improved biochemical response with elafibranor over placebo for primary biliary cholangitis according to various different criteria.

Combining slow-release bezafibrate with obeticholic acid shows treatment potential for patients with primary biliary cholangitis.

ELATIVE trial results for pruritus show benefits for both severity and impact on the quality of life of patients with primary biliary cholangitis.

Prof. Andreas Kremer provides his insights on studies on second-line obeticholic acid presented at The Liver Meeting 2023: its use in a real-world setting and as combination therapy with bezafibrate.

Dr Kris Kowdley comments on some of the key data in primary biliary cholangitis, presented at The Liver Meeting 2023, including the ELATIVE trial involving elafibranor.

Dr Gideon Hirschfield discusses some of the highlights on primary biliary cholangitis from The Liver Meeting 2023, with a focus on the RESPONSE trial of seladelpar.

Obeticholic acid positively affects liver function among patients with primary biliary cholangitis in the second-line treatment setting.

ELATIVE trial shows that elafibranor significantly improves biochemical response in patients with primary biliary cholangitis with anti-pruritic benefits.

RESPONSE trial findings show seladelpar improves markers of disease activity and reduces pruritus in patients with primary biliary cholangitis.

Denosumab is comparable to bisphosphonates for treating osteoporosis in patients with primary biliary cholangitis, but with fewer adverse effects.

Combining obeticholic acid with bezafibrate 400 mg/day shows therapeutic potential in patients with primary biliary cholangitis in two phase 2 trials.